Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Circassia starts Phase II allergy study
Circassia is conducting the study in the field of cat-dander allergy, and aims to complete the trial in the coming months. This clinical study builds on the results
Circassia is conducting the study in the field of cat-dander allergy, and aims to complete the trial in the coming months. This clinical study builds on the results
Mr. Lindsay has agreed to stay on in the role of CFO to ensure a smooth transition. Ms. Ginette joins CryoCath from Boston Scientific, where she most recently
Under the terms of the agreement, StemCyte will provide financial sponsorship for Mr. Young’s work at Rutgers’s W M Keck Center for Collaborative Neuroscience and receive exclusive commercialization
The trial collected one-year magnetic resonance imaging (MRI) data on left ventricular ejection fraction (LVEF), which reflects the fraction of blood pumped out of a ventricle with each
The pending patents cover products for diagnosis of cancer and other serious diseases. Craig Dees, CEO of Provectus, said: “These cases augment our international portfolio of twenty-six issued
The partnership with Net.Orange will bring tested and proven technology processes to the healthcare industry, beginning with the Quantum network of healthcare providers, patients and payers. Additionally, with
Barr filed its ANDA containing a paragraph IV certification for a generic Avodart product with the FDA in October 2007, and received notification of the application’s acceptance for
The agreement provides for the NCI to sponsor a clinical trial of VQD-002 in combination with erlotinib (Tarceva), an epidermal growth factor receptor (EGFR) inhibitor. Recent reports have
The investment will be used to expand the company’s service laboratory. NanoImaging Services, currently located in Northern San Diego, will relocate to a larger facility in La Jolla,
Bio-Rad is the exclusive licensee of Institute Pasteur of Paris, France, under the HIV-2 patents. Under the terms of the sublicense, Chembio has obtained non-exclusive rights to certain